ATE475674T1 - Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2 - Google Patents

Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2

Info

Publication number
ATE475674T1
ATE475674T1 AT05789182T AT05789182T ATE475674T1 AT E475674 T1 ATE475674 T1 AT E475674T1 AT 05789182 T AT05789182 T AT 05789182T AT 05789182 T AT05789182 T AT 05789182T AT E475674 T1 ATE475674 T1 AT E475674T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
angiogenic
specific substances
substances available
immunological
Prior art date
Application number
AT05789182T
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumsell
Bouteiller Philippe Le
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE475674T1 publication Critical patent/ATE475674T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
AT05789182T 2004-08-09 2005-08-09 Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2 ATE475674T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292015A EP1626059A1 (de) 2004-08-09 2004-08-09 Angiogenische und immunologische Verwendungen von anti-CD160 spezifischen Stoffen, erhältlich vom monoklonalen Antiköper CL1-R2
PCT/EP2005/009231 WO2006015886A1 (en) 2004-08-09 2005-08-09 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2

Publications (1)

Publication Number Publication Date
ATE475674T1 true ATE475674T1 (de) 2010-08-15

Family

ID=34931332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05789182T ATE475674T1 (de) 2004-08-09 2005-08-09 Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2

Country Status (10)

Country Link
US (4) US20090317401A1 (de)
EP (2) EP1626059A1 (de)
JP (1) JP5162239B2 (de)
AT (1) ATE475674T1 (de)
CA (1) CA2576627C (de)
DE (1) DE602005022589D1 (de)
DK (1) DK1776387T3 (de)
ES (1) ES2349015T3 (de)
PL (1) PL1776387T3 (de)
WO (1) WO2006015886A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2507213C2 (ru) 2005-10-04 2014-02-20 Солидженикс, Инк., Новые пептиды для лечения и профилактики иммунопатологических заболеваний, включая лечение и профилактику инфекции посредством модулирования врожденного иммунитета
EP1880729A1 (de) * 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung des löslichen CD160 zur Unterdrückung der Immunität
EP2210903A1 (de) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Monoklonale Antikörper gegen CD160 und Anwendungen davon
ES2606627T3 (es) * 2010-05-28 2017-03-24 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
EP2780360B1 (de) * 2011-11-15 2023-03-08 Sanford Burnham Prebys Medical Discovery Institute Zusammensetzungen und verfahren zur behandlung von autoimmun- und entzündungserkrankungen
BR112019008345A8 (pt) 2016-10-25 2023-03-07 Inst Nat Sante Rech Med Anticorpos monoclonais ligados à isoforma transmembrana cd160
FR3061716B1 (fr) * 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
EP3898677A1 (de) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunktionelles anti-pd-1/il-7-molekül
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN121360236A (zh) * 2019-03-01 2026-01-20 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
WO2022013256A1 (en) 2020-07-15 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd160 as a biomarker in acute myeloid leukemia
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CA3213917A1 (en) 2021-04-09 2022-10-13 Nicolas Poirier New scaffold for bifunctional molecules with improved properties
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
KR20240155347A (ko) 2022-03-09 2024-10-28 알데란 바이오테크놀로지 항-cd160 막관통 동형 항체
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
CN119998330A (zh) 2022-09-15 2025-05-13 艾维迪治疗知识产权有限公司 用于刺激nk细胞的多特异性抗原结合蛋白及其用途
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006247A1 (en) * 1993-08-27 1995-03-02 Dana-Farber Cancer Institute, Inc. Natural killer cell-specific antigen and antibodies that identify the same
WO1998021240A1 (en) * 1996-11-12 1998-05-22 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
DE60041655D1 (de) * 1999-11-15 2009-04-09 Innate Pharma Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
FR2828403B1 (fr) * 2001-08-07 2003-10-17 Abtech Utilisation de molecules solubles hla de classe 1 pour la preparation de compositions pharmaceutiques utiles pour inhiber l'angiogenese
JP2006503110A (ja) * 2002-10-09 2006-01-26 トーラーレックス， インク． エフェクタｔ細胞または制御性ｔ細胞に選択的に結合する分子およびその使用方法

Also Published As

Publication number Publication date
EP1776387A1 (de) 2007-04-25
WO2006015886A1 (en) 2006-02-16
CA2576627C (en) 2014-02-18
EP1626059A1 (de) 2006-02-15
US20120003224A1 (en) 2012-01-05
US20140120110A1 (en) 2014-05-01
DE602005022589D1 (de) 2010-09-09
US20150004170A1 (en) 2015-01-01
PL1776387T3 (pl) 2011-01-31
EP1776387B1 (de) 2010-07-28
JP2008517873A (ja) 2008-05-29
ES2349015T3 (es) 2010-12-21
DK1776387T3 (da) 2010-11-22
JP5162239B2 (ja) 2013-03-13
US20090317401A1 (en) 2009-12-24
CA2576627A1 (en) 2006-02-16
US8444978B2 (en) 2013-05-21

Similar Documents

Publication Publication Date Title
ATE475674T1 (de) Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2
DK1869085T3 (da) Hidtil ukendt anti-PLGF-antistof
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EP1461081A4 (de) Anti-cd45rb-antikörper zur verwendung bei der behandlung von autoimmunkrankheiten und transplantatabstossung
DE602005005485D1 (de) Assayvorrichtung und verfahren mit gesteuertem fluss
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE60334453D1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
FR2794865B1 (fr) Methode de detection precoce des flavivirus et ses applications
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
DK1706424T3 (da) FC-region varianter
NO20073981L (no) Criptobindende molekyler
MXPA03005273A (es) Anticuerpos producidos procarioticamente y sus usos.
ATE414106T1 (de) Pegylierte single-domain-antikörper (dab)
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
ATE526399T1 (de) Neue biologische einheiten und deren verwendung
EP1487972A4 (de) Aus mn/ca-ix-defizienten mäusen erzeugte mn/ca-ix-spezifische monoklonale antikörper und verwendungsverfahren
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
TW200510459A (en) RG1 antibodies and uses thereof
EP2275134A3 (de) Verwendung von ADCC-optimierten Antikörpern zur Behandlung von schwachen Patienten
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE60123036D1 (de) Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper, und deren verwendungen
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
EP1660128A4 (de) Anti-fcrn-antikörper zur behandlung von auto/allo-immunzuständen